Brilinta's North America Anomaly Stymies AstraZeneca, Worries Analysts
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite ticagrelor's resounding victory over Plavix in the global PLATO study, a subanalysis showing the antiplatelet drug didn't work on North Americans raises questions about how FDA will see the data.